Peter O'Donnell to Immunoconjugates
This is a "connection" page, showing publications Peter O'Donnell has written about Immunoconjugates.
Connection Strength
1.547
-
In Reply. Oncologist. 2022 10 01; 27(10):e827-e828.
Score: 0.679
-
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin. Oncologist. 2022 03 11; 27(3):e223-e232.
Score: 0.653
-
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 02; 394(13):1257-1269.
Score: 0.215